SALT LAKE CITY, May 27, 2020 /PRNewswire/ -- Co-Diagnostics,
Inc. (Nasdaq: CODX), a molecular diagnostics company
with a unique, patented platform for the development of diagnostic
tests, announced today that Company CEO Dwight Egan has been invited to present at
The Role of Cell Therapy & Clarity on Testing COVID-19 virtual conference, presented
by Maxim Group and M-Vest on Wednesday May
27th, 2020.
In addition to the Company's presentation, Co-Diagnostics will
participate in a panel discussion on the need, lack, and confusion
surrounding COVID-19 testing titled "Testing and Susceptibility –
Clearing the Air" at 12:00 PM.
The Co-Diagnostics Logix Smart™ COVID-19 test is currently
available to all clinical laboratories certified under Clinical
Laboratory Improvement Amendments (CLIA), and is authorized to be
used for the diagnosis of SARS-CoV-2, the virus that causes
COVID-19.
To access the panel discussion, please RSVP at
https://m-vest.com/insights/blog/covid-19-virtual-conference.
Panel Discussion Details:
- Panel Session Title: Testing & Susceptibility
– Clearing the Air
- Date and Time: Wednesday,
May 27, 12:00 p.m. Eastern
time (9:00 a.m. Pacific
time)
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company's technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release
contains forward-looking statements. Forward-looking statements can
be identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements
regarding the (i) use of funding proceeds, (ii) expansion of
product distribution, (iii) acceleration of initiatives in liquid
biopsy and SNP detection, (iv) use of the Company's liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company's products and markets, (vi) increased sales in
the near-term, (vii) flexibility in managing the Company's balance
sheet, (viii) anticipation of business expansion, and (ix) benefits
in research and worldwide accessibility of the CoPrimer technology
and its cost-saving and scientific advantages. Forward-looking
statements are subject to inherent uncertainties, risks and changes
in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-inc-to-present-at-covid-19-virtual-conference-hosted-by-maxim-group-on-may-27-2020-301065765.html
SOURCE Co-Diagnostics